Get the Stockscreener App
231.15
0.02%
-0.05
After Hours:
230.99
-0.16
-0.07%
Ascendis Pharma A S stock is traded at $231.15, with a volume of 631.84K.
It is down -0.02% in the last 24 hours and down -3.89% over the past month.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
See More
Previous Close:
$231.20
Open:
$232.51
24h Volume:
631.84K
Relative Volume:
1.01
Market Cap:
$15.16B
Revenue:
$1.01B
Net Income/Loss:
$581.90M
P/E Ratio:
26.05
EPS:
8.8733
Net Cash Flow:
$50.57M
1W Performance:
+10.18%
1M Performance:
-3.89%
6M Performance:
+13.97%
1Y Performance:
+33.69%
1-Day Range:
$229.35
$237.00
1-Week Range:
$208.00
$237.00
52-Week Range:
$160.86
$250.74
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
231.15 | 14.64B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-25 | Initiated | Raymond James | Strong Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-05-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | UBS | Buy |
| Sep-05-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-25-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Initiated | Stifel | Buy |
| Dec-20-23 | Initiated | Jefferies | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Neutral |
| Apr-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-04-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-03-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Aug-30-22 | Resumed | Berenberg | Buy |
| Mar-28-22 | Resumed | Wedbush | Outperform |
| Mar-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-14-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-06-22 | Initiated | Cowen | Market Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-20-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-30-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-11-21 | Resumed | Stifel | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Mar-20-20 | Initiated | Oppenheimer | Outperform |
| Oct-11-19 | Initiated | Morgan Stanley | Overweight |
| Mar-25-19 | Initiated | Evercore ISI | Outperform |
| Jan-24-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-19 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-18 | Initiated | Stifel | Buy |
| Apr-02-18 | Reiterated | Leerink Partners | Mkt Perform |
| May-11-17 | Initiated | JP Morgan | Overweight |
| Mar-09-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Feb-09-17 | Initiated | Credit Suisse | Outperform |
| Sep-26-16 | Initiated | Wedbush | Outperform |
View All
Ascendis Pharma A S Stock (ASND) Latest News
Oppenheimer reiterates Ascendis Pharma stock rating on drug data - Investing.com
Oppenheimer reiterates Ascendis Pharma stock rating on drug data By Investing.com - Investing.com Canada
Ascendis Pharma Posts Strong 3.5-Year Phase 3 Data for TransCon PTH in Hypoparathyroidism - TipRanks
Long-term TransCon PTH data from Ascendis Pharma (ASND) show sustained benefits - Stock Titan
Ascendis Pharma A/S (ASND) Presents at Endocrine Society's Annual Meeting (ENDO 2026)Slideshow - Seeking Alpha
Ascendis Pharma completes Phase 3 PaTHway Trial - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
(ASND) Risk Channels and Responsive Allocation - Stock Traders Daily
Ascendis Pharma Reports Sustained Efficacy and Safety of TransCon PTH in Phase 3 PaTHway Trial for Hypoparathyroidism After Three and a Half Years - Quiver Quantitative
Hormone shot helps hypoparathyroidism patients cut daily calcium and vitamin D - Stock Titan
Ascendis Pharma's TransCon PTH shows 5-year success in hypoparathyroidism treatment, boosting stock. - Pluang
Why Is Ascendis Pharma Stock Gaining Friday? - Benzinga
Ascendis boasts of long-term Yorvipath data for hypoparathyroidism - MSN
Ascendis Pharma Reports Five-Year TransCon PTH Data Showing Sustained Benefits in Hypoparathyroidism - TipRanks
Five-year TransCon PTH trial results reported by Ascendis Pharma (ASND) - Stock Titan
Ascendis reports 5-year data for hypoparathyroidism drug - Investing.com UK
Ascendis reports 5-year data for hypoparathyroidism drug By Investing.com - Investing.com Australia
Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years - Moomoo
5-year trial: drug frees most hypoparathyroidism patients from supplements - Stock Titan
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic - GlobeNewswire
Ascendis Pharma Named Among Top Profitable Growth Stocks: Market Recognition BuildsMid-Term Outlook - newsline.com
Ascendis Pharma grants 27,030 employee warrants at $213.23 per share By Investing.com - Investing.com South Africa
Ascendis Pharma Grants New Employee Warrants as Part of Updated Equity Incentive Plan - TipRanks
Ascendis Pharma grants 27,030 employee warrants at $213.23 per share - Investing.com
[6-K] Ascendis Pharma A/S Current Report (Foreign Issuer) | ASND SEC FilingForm 6-K - Stock Titan
Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy - Yahoo Finance
Oppenheimer reiterates Ascendis Pharma stock rating amid ITC case By Investing.com - Investing.com Australia
Oppenheimer reiterates Ascendis Pharma stock rating amid ITC case - Investing.com
10 Most Profitable Growth Stocks to Buy - Insider Monkey
Ascendis Pharma A/S to Present Latest Data on Endocrinology Rare Disease Programs at ENDO 2026 - Quiver Quantitative
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 - GlobeNewswire Inc.
Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness - simplywall.st
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness - Yahoo Finance
Why Ascendis Pharma Stock Is Sinking Today - TipRanks
Ascendis Pharma A/S (ASND) Stock Analysis: Unlocking a 40% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Capital International Ltd. CA Sells 4,811 Shares of Ascendis Pharma A/S $ASND - MarketBeat
ASND Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Ascendis Pharma A/S Stock 12‑Month Price Target Raised to $295.6, Implies 40% Upside - TradingView
TD Asset Management Inc Has $49.90 Million Position in Ascendis Pharma A/S $ASND - MarketBeat
The Option Play Of The Week (NASDAQ:ASND) - Seeking Alpha
Westfield Capital Management Co. LP Cuts Stake in Ascendis Pharma A/S $ASND - MarketBeat
Ascendis Pharma reports trial data on achondroplasia treatment - Investing.com
Ascendis Pharma’s YUVIWEL gains orphan drug exclusivity in U.S. - Investing.com
ASND Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; Stock Falls 1%Estimate Dispersion - newsline.com
Insider Buying: Scott Smith Acquires Additional Shares of Ascend - GuruFocus
Ascendis Pharma A/S - MLQ.ai
Insider Buying: Scott Smith Acquires Additional Shares of Ascendis Pharma AS (ASND) - GuruFocus
Ascendis Pharma (ASND) CFO acquires 100 Ordinary Shares in open-market buy - Stock Titan
AlphaCentric Life Sciences and Healthcare Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
(ASND) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Insider Buying: Jean Bienaime Acquires Additional Shares of Asce - GuruFocus
Ascendis Pharma A S Stock (ASND) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ascendis Pharma A S Stock (ASND) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
May 29 '26 |
Buy |
223.12 |
500 |
111,562 |
900 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer |
May 29 '26 |
Buy |
223.32 |
250 |
55,830 |
4,267 |
| BIENAIME JEAN JACQUES | Director |
May 26 '26 |
Buy |
237.80 |
400 |
95,120 |
400 |
| JENSEN FLEMMING STEEN | See Remarks |
May 11 '26 |
Sale |
238.49 |
19,460 |
4,641,021 |
0 |
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):